ARIUS announces first quarter fiscal 2008 financi... ( TORONTO April 11 / ARIUS Research...)

ARIUS announces first quarter fiscal 2008 financial results

Date:4/11/2008

TORONTO, April 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the first fiscal quarter of 2008, ended February 29, 2008.

"During the quarter, we continued to focus on advancing our antibody drugs efficiently and rapidly towards human clinical trials. Most significantly, we completed our pre-IND meeting with the US FDA for our lead CD44 Cancer Stem Program," said Dr. David Young, President and CEO of ARIUS. "We also presented new findings from our lead programs, including data from our CD9 Cancer Stem Cell program in collaboration with Dr. John Dick, a pioneer in the cancer stem cell field. Maintaining this momentum, five ARIUS abstracts have been selected for presentation in the upcoming AACR Annual meeting this month, demonstrating the scientific community's ongoing interest in our programs and the high quality of our research."

Program Updates:

CD44 Cancer Stem Cell Program

- Selected to present two CD44-focused posters at AACR the American

Association for Cancer Research (AACR) Annual Meeting held from

April 12-16, 2008 in San Diego, California.

- Held meeting with FDA to discuss plans for the upcoming

IND submission.

- Prepared to file a Phase I IND application and begin human

clinical trials for the CD44 Cancer Stem Cell program in 2008.

Trop-2 Signal Transduction Program

- Completed first toxicology studies.

- Selected to present a Trop-2-focused poster at AACR Annual

Meeting.

- Engaged Laureate Pharma Inc. for cGMP manufacturing of humanized

antibody for Phase 1 clinical supply. A cell line producing the

humanized anti-Trop-2 antibody was successfully transferred to

Laureate.

- Pr
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results

Post Your Comments:

ARIUS announces first quarter fiscal 2008 financi...( TORONTO April 11 / ARIUS Research...)